{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:33:27Z","timestamp":1783625607451,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.016","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:04:58Z","timestamp":1254218698000},"page":"S222-S230","source":"Crossref","is-referenced-by-count":56,"special_numbering":"S3","title":["High-Risk Childhood Acute Lymphoblastic Leukemia"],"prefix":"10.3816","volume":"9","author":[{"given":"Deepa","family":"Bhojwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.016_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.016_bib2","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2006-07-038299","article-title":"Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia","volume":"110","author":"Nachman","year":"2007","journal-title":"Blood"},{"issue":"(suppl 1)a","key":"10.3816\/CLM.2009.s.016_bib3","first-page":"S42","article-title":"Risk-adapted therapy for children with acute lymphoblastic leukemia (ALL): the Children's Oncology Group (COG) approach","volume":"87","author":"Carroll","year":"2008","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2009.s.016_bib4","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"Moricke","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2007.12.3927","article-title":"Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy","volume":"26","author":"Aric\u00f2","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2006.06.8312","article-title":"Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial","volume":"25","author":"Ribera","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib7","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1182\/blood-2004-04-1616","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital","volume":"104","author":"Pui","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib9","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2401960","article-title":"Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCGEORTC report. Children Leukemia Cooperative Group","volume":"14","author":"Vilmer","year":"2000","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.016_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/pbc.10461","article-title":"Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation","volume":"42","author":"Saarinen-Pihkala","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.3816\/CLM.2009.s.016_bib11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3324\/haematol.12365","article-title":"Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15","volume":"93","author":"Manabe","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.016_bib12","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib13","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2002-08-2372","article-title":"Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92","volume":"102","author":"Harms","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk-and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib15","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B","article-title":"Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review","volume":"80","author":"Gaynon","year":"1997","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.016_bib16","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib17","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group","volume":"95","author":"Schrappe","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib18","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/sj.leu.2401939","article-title":"Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995","volume":"14","author":"Gaynon","year":"2000","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.016_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V100.1.43","article-title":"Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia","volume":"100","author":"Sandlund","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib20","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.016_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.seminhematol.2008.09.001","article-title":"Minimal residual disease in acute lymphoblastic leukemia","volume":"46","author":"Campana","year":"2009","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2009.s.016_bib22","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.leu.2401459","article-title":"Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"13","author":"Neale","year":"1999","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.016_bib24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2008.5","article-title":"Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOPBFM ALL 2000 for childhood acute lymphoblastic leukemia","volume":"22","author":"Flohr","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.016_bib25","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/sj.leu.2402552","article-title":"Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL","volume":"16","author":"Bader","year":"2002","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.016_bib26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2403283","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse","volume":"18","author":"Coustan-Smith","year":"2004","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.016_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2006-01-0066","article-title":"A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome","volume":"108","author":"Coustan-Smith","year":"2006","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.3816\/CLM.2009.s.016_bib28","first-page":"S124","article-title":"Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia","volume":"83","author":"Pui","year":"2004","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2009.s.016_bib29","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.016_bib30","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","article-title":"Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"12","author":"Cohen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.016_bib31","doi-asserted-by":"crossref","first-page":"528a","DOI":"10.1182\/blood.V108.11.1864.1864","article-title":"Nelarabine can be safely incorporated into an intensive, multiagent chemotherapy regimen for the treatment of T-cell acute lymphoblastic leukemia in children: A report of the Choldren's Oncology Group AALL00P2 protocol for T-cell leukemia","volume":"108","author":"Dunsmore","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib32","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2007.12.2820","article-title":"Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study","volume":"26","author":"Oudot","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.911.911","article-title":"Philadelphia chromosome negative very high risk acute lymphoblastic leukemia in children and adolescents: The impact of intensified chemotherapy on early event free survival in Children's Oncology Group study AALL0031","volume":"112","author":"Schultz","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(05)66998-X","article-title":"Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study","volume":"366","author":"Balduzzi","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.016_bib35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving towards individualized medicine with pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.s.016_bib36","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.293.12.1485","article-title":"Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia","volume":"293","author":"Stanulla","year":"2005","journal-title":"JAMA"},{"key":"10.3816\/CLM.2009.s.016_bib37","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2007-09-114082","article-title":"Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"111","author":"Davies","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jama.2009.7","article-title":"Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia","volume":"301","author":"Yang","year":"2009","journal-title":"JAMA"},{"key":"10.3816\/CLM.2009.s.016_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1182\/blood-2004-04-1552","article-title":"Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia","volume":"105","author":"Cario","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib40","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2006-01-0322","article-title":"Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2","volume":"108","author":"Flotho","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib41","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1200\/JCO.2007.11.8166","article-title":"High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS","volume":"25","author":"Cario","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib42","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbmt.2006.09.013","article-title":"Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report","volume":"13","author":"Satwani","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.016_bib43","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(07)60915-5","article-title":"Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study","volume":"369","author":"Eapen","year":"2007","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.016_bib44","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1182\/blood-2007-06-098020","article-title":"Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies","volume":"112","author":"Kurtzberg","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib45","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1200\/JCO.2006.06.2679","article-title":"Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95","volume":"24","author":"Schrauder","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.3816\/CLM.2009.s.016_bib46","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/bmt.2008.58","article-title":"Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials","volume":"41","author":"Schrauder","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.016_bib47","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(02)08782-2","article-title":"Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region","volume":"359","author":"Pui","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.016_bib48","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLM.2009.s.016_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.016_bib50","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2005-07-3011","article-title":"Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group","volume":"108","author":"Hilden","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib51","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.1985.3.11.1513","article-title":"Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group","volume":"3","author":"Reaman","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib52","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.leu.2403253","article-title":"In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype","volume":"18","author":"Ramakers-van Woerden","year":"2004","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.016_bib53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cppeds.2007.12.001","article-title":"The ABCs of infant leukemia","volume":"38","author":"Zweidler-McKay","year":"2008","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"(suppl 1)a","key":"10.3816\/CLM.2009.s.016_bib54","first-page":"S5","article-title":"Efficacy of MLL-Baby protocol in infants with MLL-rearranged B-lineage phenotype leukemia","volume":"87","author":"Fechina","year":"2008","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2009.s.016_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat Genet"},{"key":"10.3816\/CLM.2009.s.016_bib56","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","article-title":"Targeting FLT3 in primary MLL-generearranged infant acute lymphoblastic leukemia","volume":"106","author":"Stam","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1535-6108(03)00003-5","article-title":"Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification","volume":"3","author":"Armstrong","year":"2003","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2009.s.016_bib58","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood.V99.11.3885","article-title":"A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo","volume":"99","author":"Levis","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib59","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/sj.leu.2404277","article-title":"Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner","volume":"20","author":"Brown","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.016_bib60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.leu.2404074","article-title":"Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia","volume":"20","author":"Stam","year":"2006","journal-title":"Leukemia"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.016_bib61","first-page":"529a","article-title":"Hematopoetic stem cell transplant (HSCT) versus intensive chemotherapy in infant acute lymphoblastic leukemia (ALL)","volume":"25","author":"Dreyer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib62","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2004-08-3312","article-title":"Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia","volume":"105","author":"Sanders","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib63","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbmt.2005.08.031","article-title":"Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation","volume":"11","author":"Jacobsohn","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.016_bib64","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/sj.leu.2404903","article-title":"Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group","volume":"21","author":"Tomizawa","year":"2007","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.016_bib65","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q","article-title":"Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group","volume":"83","author":"Uckun","year":"1998","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.016_bib66","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.016_bib67","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib69","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib70","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"key":"10.3816\/CLM.2009.s.016_bib71","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib72","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosomepositive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib73","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.016_bib74","doi-asserted-by":"crossref","first-page":"318a","DOI":"10.1182\/blood.V110.11.1049.1049","article-title":"Dasatinib (Spyrel) in children and adolescents with relapsed or refractory leukemia: Preliminary results of the CA180018 Phase I\/II Study from the ITCC consortium","volume":"110","author":"Zwaan","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib75","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-07-5015","article-title":"Nilotinib","volume":"14","author":"Deininger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.016_bib76","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315Ipositive chronic myelogenous leukemia","volume":"14","author":"Quintas-Cardama","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.016_bib77","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJM200004063421402","article-title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"342","author":"Arico","year":"2000","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.016_bib78","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2141.2002.03838.x","article-title":"Prospective molecular monitoring of BCR\/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response","volume":"119","author":"Cazzaniga","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.016_bib79","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.bmt.1705904","article-title":"Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia","volume":"41","author":"Fielding","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.016_bib80","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1703951","article-title":"A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society","volume":"31","author":"Esperou","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.016_bib81","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib82","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood-2006-08-040436","article-title":"Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.016_bib83","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.016_bib84","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3816\/CLM.2009.s.016_bib85","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib86","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1200\/JCO.2007.14.4519","article-title":"Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study. [corrected]","volume":"26","author":"Bhojwani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib87","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.1998.16.2.527","article-title":"Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group","volume":"16","author":"Uckun","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib88","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(08)70070-6","article-title":"Current management and challenges of malignant disease in the CNS in paediatric leukaemia","volume":"9","author":"Pui","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLM.2009.s.016_bib89","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrd2240","article-title":"New therapeutic strategies for the treatment of acute lymphoblastic leukaemia","volume":"6","author":"Pui","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.3816\/CLM.2009.s.016_bib90","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.016_bib91","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.seminhematol.2008.09.002","article-title":"Pharmacogenetics in acute lymphoblastic leukemia","volume":"46","author":"Cheok","year":"2009","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2009.s.016_bib92","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T15:47:07Z","timestamp":1590162427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":92,"alternative-id":["S1557919011703444"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.016","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}